CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 550 enrolled
Drug / intervention
fluticasone furoate nasal spray +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00682643
NCT00682643Phase 4Completed

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110mcg in Adults and Adolescents 12 Years of Age and Older With Perennial Allergic Rhinitis

GlaxoSmithKline·interventional·Posted May 22, 2008·Updated Jan 13, 2017

In Brief

A Phase 4 clinical trial evaluating fluticasone furoate nasal spray and vehicle placebo nasal spray for Rhinitis, Allergic, Perennial. Completed, enrolled 550 participants across 56 sites.

Detailed Summary

The purpose of this study is to assess long-term ocular safety of fluticasone furoate nasal spray in adult and adolescent subjects diagnosed with perennial allergic rhinitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 22, 2008
Enrollment StartJun 1, 2008
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 18.1 years ago

Interventions

fluticasone furoate nasal spraydrug

fluticasone furoate nasal spray

vehicle placebo nasal spraydrug

placebo